hackint0sh/temp-data huggingface dataset:
protocolSection identificationModule nctId: NCT06261164, orgStudyIdInfo id: 01-19-373- 2/23, briefTitle: Population Pharmacokinetic Model of Amikacin and Vancomycin in Critically Ill Patients, statusModule overallStatus: RECRUITING, startDateStruct date: 2024-01-31, primaryCompletionDateStruct date: 2024-12-31, completionDateStruct date: 2025-01-31, studyFirstPostDateStruct date: 2024-02-15, lastUpdatePostDateStruct date: 2024-02-15, sponsorCollaboratorsModule leadSponsor name: University Clinical Centre of Republic of Srpska, class: OTHER, descriptionModule briefSummary: The object of the scientific research is the characterization of the pharmacokinetic profile and the investigation of factors of pharmacokinetic variability of amikacin and vacnomycin in critically ill patients with a diagnosis of sepsis-like condition (SIRS), hospital-acquired sepsis and/or septic shock and who are on extracorporeal therapy with Cytosorb® and Oxiris® adsorbents., conditionsModule conditions: Sepsis, designModule studyType: OBSERVATIONAL, designInfo observationalModel: COHORT, timePerspective: PROSPECTIVE, enrollmentInfo count: 20, type: ESTIMATED, armsInterventionsModule interventions name: Cytosorb® and Oxiris® adsorbents, outcomesModule primaryOutcomes measure: Development of population pharmacokinetic model, eligibilityModule sex: ALL, stdAges: CHILD, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Department of Medical Intensive Care Medicine, status: RECRUITING, city: Banja Luka, zip: 78000, country: Bosnia and Herzegovina, contacts name: Nikolina Spiric, MPharm, role: CONTACT, phone: +38751342295, email: nikolina.spiric@kc-bl.com, contacts name: Pedja Kovacevic, Prof., role: SUB_INVESTIGATOR, geoPoint lat: 44.77842, lon: 17.19386, hasResults: False
protocolSection identificationModule nctId: NCT06261151, orgStudyIdInfo id: Zhongshan-HHY-03, briefTitle: Preoperative Nutritional Status Associated With Delayed Discharge in Elderly Patients Undergoing Gastrectomy, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-03-01, primaryCompletionDateStruct date: 2024-12-31, completionDateStruct date: 2025-03-31, studyFirstPostDateStruct date: 2024-02-15, lastUpdatePostDateStruct date: 2024-02-15, sponsorCollaboratorsModule leadSponsor name: Shanghai Zhongshan Hospital, class: OTHER, descriptionModule briefSummary: Gastric cancer (GC) remains the 5th most common cancer worldwide and had the second- highest mortality rate in China. The population of elder patients with GC has been increasing because of the high prevalence of H. pylori infection and increasing life expectancy. Elderly GC patients face several challenges during treatment, such as comorbidities, organ dysfunction, immunosuppression, and delayed recovery. Advanced age is associated with a higher rate of postoperative complications shortly after surgical treatment, and lower 5-year overall survival as long-term outcome.In China, the prevalence of malnutrition in hospitalized patients is around 12.6% to 46.19%. Malnutrition is one of the great risk factors of adverse clinical outcomes in elderly patients with GC. The nutritional status at the time of diagnosis was independently associated with postoperative complications, overall survival, and disease-free survival. The condition can be caused by mechanical obstruction of the digestive tract or anorexia-cachexia syndrome, leading to insufficient protein or energy intake and absorption disorder. Nutrition screening, assessment, and intervention are important steps in nutritional management.Previous studies mostly focused on hospitalized internal medical patients. Only a few studies focused on surgical patients regardless of age. Therefore, in this retrospective study, we are going to investigate the nutritional status and perioperative nutritional support of geriatric surgical patients with GC, and provide a basis for implementing an effective nutritional intervention., conditionsModule conditions: Preoperative Nutritional Status and Risk Factors Associated With Elderly Patients Undergoing Gastrectomy, designModule studyType: OBSERVATIONAL, designInfo observationalModel: COHORT, timePerspective: RETROSPECTIVE, enrollmentInfo count: 1000, type: ESTIMATED, armsInterventionsModule interventions name: Clinical data collection, outcomesModule primaryOutcomes measure: The preoperative nutritional status of elderly patients underwent gastrectomy, eligibilityModule sex: ALL, minimumAge: 60 Years, maximumAge: 90 Years, stdAges: ADULT, stdAges: OLDER_ADULT, hasResults: False
protocolSection identificationModule nctId: NCT06261138, orgStudyIdInfo id: RSR-HCC-2019-001, briefTitle: Survival Analysis: TACE vs. Combination Therapy in HCC, statusModule overallStatus: COMPLETED, startDateStruct date: 2019-02-01, primaryCompletionDateStruct date: 2023-03-31, completionDateStruct date: 2023-10-31, studyFirstPostDateStruct date: 2024-02-15, lastUpdatePostDateStruct date: 2024-02-15, sponsorCollaboratorsModule leadSponsor name: Zhejiang University, class: OTHER, descriptionModule briefSummary: This retrospective observational study aimed to assess potential improvements associated with systemic therapies in patients receiving transarterial chemoembolization (TACE) for initially unresectable HCC., conditionsModule conditions: Hepatocellular Carcinoma, designModule studyType: OBSERVATIONAL, designInfo observationalModel: COHORT, timePerspective: RETROSPECTIVE, enrollmentInfo count: 279, type: ACTUAL, armsInterventionsModule interventions name: Transarterial chemoembolization, interventions name: Systemic treatment, outcomesModule primaryOutcomes measure: Progression Free Survival (PFS) per mRECIST, secondaryOutcomes measure: 12 months PFS rate, secondaryOutcomes measure: Overall survival (OS), secondaryOutcomes measure: Objective Response Rate (ORR) per mRECIST, secondaryOutcomes measure: Disease Control Rate (DCR) per mRECIST, secondaryOutcomes measure: Adverse events (AEs), eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 75 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: First Affiliated Hospital, Medical College of Zhejiang University, city: Hangzhou, state: Zhejiang, zip: 310003, country: China, geoPoint lat: 30.29365, lon: 120.16142, hasResults: False
protocolSection identificationModule nctId: NCT06261125, orgStudyIdInfo id: SL-B2023-718, briefTitle: Combination of SBRT, PD-L1 Inhibitor, and Lenvatinib in Hepatocellular Carcinoma (HSBRT2401), acronym: HSBRT2401, statusModule overallStatus: RECRUITING, startDateStruct date: 2024-03-10, primaryCompletionDateStruct date: 2026-06-30, completionDateStruct date: 2028-06-30, studyFirstPostDateStruct date: 2024-02-15, lastUpdatePostDateStruct date: 2024-03-12, sponsorCollaboratorsModule leadSponsor name: Mian XI, class: OTHER, descriptionModule briefSummary: Abdominal lymph node metastasis (LNM) is one of the major modes of extrahepatic metastasis in hepatocellular carcinoma (HCC). Immunotherapy targeting the PD-1/PD-L1 checkpoints combined with targeted therapy is the standard treatment for HCC with abdominal LNM, but the outcome remains very poor, with an objective response rate of 5% to 30%. Previous studies have demonstrated that stereotactic body radiotherapy (SBRT) is an effective local treatment for HCC with abdominal LNM, with a high response rate of 60% to 80%. However, intrahepatic dissemination and distant metastasis remains the major recurrence pattern after SBRT in these patients, suggesting radiotherapy should be combined with systematic treatment. Recently, the combination of immunotherapy with SBRT has shown promising activity in HCC. The aim of this study was to investigate the efficacy and safety of SBRT followed by adebrelimab (an anti-PD-L1 antibody) and lenvatinib in HCC patients with portal abdominal LNM., conditionsModule conditions: Hepatocellular Carcinoma, designModule studyType: INTERVENTIONAL, phases: PHASE2, designInfo allocation: NON_RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 60, type: ESTIMATED, armsInterventionsModule interventions name: Stereotactic body radiotherapy, interventions name: Adebrelimab, interventions name: Lenvatinib, outcomesModule primaryOutcomes measure: Progression-free survival (PFS), secondaryOutcomes measure: Overall survival (OS), secondaryOutcomes measure: Overall response rate (ORR), secondaryOutcomes measure: Disease control rate (DCR), secondaryOutcomes measure: Duration of response (DOR), secondaryOutcomes measure: Treatment-related adverse events, otherOutcomes measure: Correlation between serum cytokines and overall survival and immune-related adverse events, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 75 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Mian Xi, status: RECRUITING, city: Guangzhou, state: Guangdong, zip: 510060, country: China, contacts name: Mian Xi, MD, role: CONTACT, phone: +862087343385, email: ximian@sysucc.org.cn, contacts name: Mian Xi, MD, role: PRINCIPAL_INVESTIGATOR, geoPoint lat: 23.11667, lon: 113.25, hasResults: False
protocolSection identificationModule nctId: NCT06261112, orgStudyIdInfo id: B.30.2.ATA.01.11/285, briefTitle: The Effect of Using a Kaleidoscope on Fear and Pain in Children, statusModule overallStatus: RECRUITING, startDateStruct date: 2022-05-07, primaryCompletionDateStruct date: 2024-05-01, completionDateStruct date: 2024-05-01, studyFirstPostDateStruct date: 2024-02-15, lastUpdatePostDateStruct date: 2024-02-15, sponsorCollaboratorsModule leadSponsor name: Mihriban Culha, class: OTHER, descriptionModule briefSummary: The research was conducted in randomized controlled experimental type between May 2022 and December2023. The universe of the research consisted of children and their parents who were diagnosed with a fracture, applied to the Orthopedic outpatient clinic and Emergency department of the Erzurum Ataturk University Health Research and Application Center and referred to the Orthopedic clinic, and decided to undergo a cast procedure for treatment. The sample of the research consisted of a total of 70 children and their parents, including 35 control groups and 35 kaleidoscope groups, who met the research criteria from this universe. The children in the kaleidoscope group were shown the kaleidoscope. No intervention other than routine application was applied to the control group. "Introductory Information Form", "Wong-Baker Facial Expressions Rating Scale and Child Fear Scale were used in the collection of data., conditionsModule conditions: Fracture; Complication Orthopedic Procedure, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, interventionModelDescription: Parallel Assigment, primaryPurpose: SUPPORTIVE_CARE, maskingInfo masking: SINGLE, maskingDescription: single /investigatör), whoMasked: INVESTIGATOR, enrollmentInfo count: 70, type: ESTIMATED, armsInterventionsModule interventions name: kaleidescope, outcomesModule primaryOutcomes measure: Child Fear Scale (CFS), secondaryOutcomes measure: Facial Expressions Rating Scale, eligibilityModule sex: ALL, minimumAge: 6 Years, maximumAge: 12 Years, stdAges: CHILD, contactsLocationsModule locations facility: Ataturk University, status: RECRUITING, city: Erzurum, zip: 25240, country: Turkey, contacts name: Mihriban ÇULHA, role: CONTACT, phone: 05070926243, email: mihriban2560@outlook.com, geoPoint lat: 39.90861, lon: 41.27694, hasResults: False
protocolSection identificationModule nctId: NCT06261099, orgStudyIdInfo id: 037, briefTitle: Telerehabilitation-Based Early Upper Extremity Training in Stroke Patients, statusModule overallStatus: RECRUITING, startDateStruct date: 2024-02-08, primaryCompletionDateStruct date: 2025-02-27, completionDateStruct date: 2025-11-27, studyFirstPostDateStruct date: 2024-02-15, lastUpdatePostDateStruct date: 2024-02-15, sponsorCollaboratorsModule leadSponsor name: Suleyman Demirel University, class: OTHER, descriptionModule briefSummary: Telerehabilitation method, which is an alternative to face-to-face rehabilitation practices for stroke patients who need intensive, regular and long-term rehabilitation in the early period, has been popularly used in recent years. Telerehabilitation is a practice in which the patient participates in the treatment via digital media without the need for the patient to come to the clinic., conditionsModule conditions: Stroke, Acute, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: CROSSOVER, interventionModelDescription: prospective double-blind, randomized controlled trial, primaryPurpose: TREATMENT, maskingInfo masking: QUADRUPLE, maskingDescription: Sealed envelopes will be prepared in advance for randomization and will be marked with numbers 1 and 2, indicating whether they are a study group or a control group. Randomization will be done by a third party unaware of the study content. Randomization order tracking will be done with sequentially numbered containers. Patients participating in the study will be blinded to which treatment group they will be included in., whoMasked: PARTICIPANT, whoMasked: CARE_PROVIDER, whoMasked: INVESTIGATOR, whoMasked: OUTCOMES_ASSESSOR, enrollmentInfo count: 40, type: ESTIMATED, armsInterventionsModule interventions name: control + working group, outcomesModule primaryOutcomes measure: Mini Mental Test, primaryOutcomes measure: Fugl Meyer Motor Function Scale, primaryOutcomes measure: Laser-pointer Assisted Angle Reproduction Test, primaryOutcomes measure: Modified Barthel Index, primaryOutcomes measure: Reaching Performance Scale, eligibilityModule sex: ALL, minimumAge: 30 Years, maximumAge: 65 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Güler Ertuğrul, status: RECRUITING, city: Kocaeli, state: İ̇zmi̇t, country: Turkey, contacts name: GÜLER ERTUĞRUL, role: CONTACT, phone: +90 531 950 05 90, email: gertugrul004@gmail.com, geoPoint lat: 39.62497, lon: 27.51145, locations facility: Suleyman Demirel University, status: RECRUITING, city: Isparta, state: Merkez, country: Turkey, contacts name: MEHMET DURAY, role: CONTACT, phone: +90 506 473 11 65, email: mehmetduray@sdu.edu.tr, geoPoint lat: 37.76444, lon: 30.55222, hasResults: False
protocolSection identificationModule nctId: NCT06261060, orgStudyIdInfo id: 2023-0918, secondaryIdInfos id: NCI-2024-01333, type: OTHER, domain: NCI-CTRP Clinical Registry, briefTitle: Low-Dose Sirolimus to Increase Hematopoietic Function in Patients With RUNX1 Familial Platelet Disorder, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-08-31, primaryCompletionDateStruct date: 2026-06-11, completionDateStruct date: 2028-06-11, studyFirstPostDateStruct date: 2024-02-15, lastUpdatePostDateStruct date: 2024-03-07, sponsorCollaboratorsModule leadSponsor name: M.D. Anderson Cancer Center, class: OTHER, descriptionModule briefSummary: To learn about the safety and effects of low-dose sirolimus in participants with RUNX1-FPD., conditionsModule conditions: Familial Platelet Disorder, conditions: Hematopoietic, designModule studyType: INTERVENTIONAL, phases: PHASE2, designInfo allocation: NA, interventionModel: SINGLE_GROUP, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 6, type: ESTIMATED, armsInterventionsModule interventions name: Sirolimus, outcomesModule primaryOutcomes measure: Safety and adverse events (AEs), eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: MD Anderson Cancer Center, city: Houston, state: Texas, zip: 77030, country: United States, contacts name: Courtney DiNardo, MD, role: CONTACT, phone: 713-794-1141, email: cdinardo@mdanderson.org, contacts name: Courtney DiNardo, MD, role: PRINCIPAL_INVESTIGATOR, geoPoint lat: 29.76328, lon: -95.36327, hasResults: False
protocolSection identificationModule nctId: NCT06261047, orgStudyIdInfo id: SDZLEC2023-389-02, briefTitle: Radiotherapy Delays Second-line Drug Therapy for Oligo Progressive Primary Liver Cancer, statusModule overallStatus: RECRUITING, startDateStruct date: 2024-01-01, primaryCompletionDateStruct date: 2026-01-01, completionDateStruct date: 2026-01-01, studyFirstPostDateStruct date: 2024-02-15, lastUpdatePostDateStruct date: 2024-02-15, sponsorCollaboratorsModule leadSponsor name: Shandong Cancer Hospital and Institute, class: OTHER, descriptionModule briefSummary: Recent years have seen significant advancements in the treatment landscape of advanced hepatocellular carcinoma (HCC), with the emergence of targeted and immunotherapy strategies reshaping first-line therapy. Sorafenib, a multi-targeted tyrosine kinase inhibitor, initially set the standard, followed by approvals for lenvatinib, regorafenib, cabozantinib, and ramucirumab. Immunotherapy, particularly combinations like atezolizumab with bevacizumab, has shown superior efficacy over sorafenib. Despite these advances, second-line therapies offer limited progression-free survival (mPFS: 2-3 months), necessitating new approaches. Radiotherapy, bolstered by technological advancements, has shown promise. Techniques like stereotactic body radiotherapy (SBRT) combined with PD-1 inhibitors achieve significant response rates and survival benefits. Combining radiotherapy with targeted immunotherapy has also demonstrated improved outcomes. Radiotherapy, especially in oligometastatic HCC, is increasingly favored due to its ability to enhance local control without increasing toxicity. These developments underscore the evolving landscape of HCC treatment towards personalized and multimodal approaches., conditionsModule conditions: Hepatocellular Carcinoma, conditions: Radiotherapy, designModule studyType: OBSERVATIONAL, designInfo observationalModel: COHORT, timePerspective: PROSPECTIVE, enrollmentInfo count: 36, type: ESTIMATED, armsInterventionsModule interventions name: radiotherapy, outcomesModule primaryOutcomes measure: Progression free survival, secondaryOutcomes measure: Overall response rate, secondaryOutcomes measure: Overall survial, secondaryOutcomes measure: Disease control rate, secondaryOutcomes measure: Duration of control, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 75 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Jinbo Yue, status: RECRUITING, city: Jinan, state: Shandong, zip: 250000, country: China, contacts name: jinbo yue, role: CONTACT, phone: +86053167626442, email: yuejinbo@hotmail.com, geoPoint lat: 36.66833, lon: 116.99722, hasResults: False
protocolSection identificationModule nctId: NCT06261034, orgStudyIdInfo id: 23-008765, secondaryIdInfos id: 8K12AR084222-15, type: NIH, link: https://reporter.nih.gov/quickSearch/8K12AR084222-15, briefTitle: A Study of Sex Differences in Neurocirculatory Control, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-05, primaryCompletionDateStruct date: 2027-03, completionDateStruct date: 2027-03, studyFirstPostDateStruct date: 2024-02-15, lastUpdatePostDateStruct date: 2024-04-10, sponsorCollaboratorsModule leadSponsor name: Mayo Clinic, class: OTHER, collaborators name: National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), descriptionModule briefSummary: The purpose of this study is to investigate potential sex differences in neurocirculatory control of blood pressure in patients with untreated obstructive sleep apnea (OSA)., conditionsModule conditions: Obstructive Sleep Apnea, designModule studyType: OBSERVATIONAL, designInfo observationalModel: COHORT, timePerspective: CROSS_SECTIONAL, enrollmentInfo count: 60, type: ESTIMATED, outcomesModule primaryOutcomes measure: Blood pressure, primaryOutcomes measure: Arterial stiffness, primaryOutcomes measure: Endothelial function, secondaryOutcomes measure: Sympathetic nerve burst frequency, secondaryOutcomes measure: Sympathetic nerve burst incidence, secondaryOutcomes measure: Sympathetic nerve burst amplitude (AU), secondaryOutcomes measure: Total muscle sympathetic nerve activity (MSNA), otherOutcomes measure: Cerebral autoregulation, otherOutcomes measure: Sympathetic action potentials per burst, otherOutcomes measure: Sympathetic action potential clusters per burst, otherOutcomes measure: Sympathetic action potential conduction latency of each cluster, otherOutcomes measure: Immune function, otherOutcomes measure: Urinary Extracellular Vesicle Presence and Content, otherOutcomes measure: Plasma Extracellular Vesicle Presence and Content, eligibilityModule sex: ALL, minimumAge: 20 Years, maximumAge: 70 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Mayo Clinic in Rochester, city: Rochester, state: Minnesota, zip: 55905, country: United States, contacts name: Joshua Bock, PhD, role: CONTACT, phone: 507-422-0768, email: bock.joshua@mayo.edu, contacts name: Ian Greenlund, PhD, role: CONTACT, phone: (507) 422-3411, email: Greenlund.Ian@mayo.edu, contacts name: Virend Somers, MD, PhD, role: PRINCIPAL_INVESTIGATOR, geoPoint lat: 44.02163, lon: -92.4699, hasResults: False
protocolSection identificationModule nctId: NCT06261021, orgStudyIdInfo id: INNO-6051, briefTitle: Study to Evaluate the Efficacy of Ruxolitinib 1.5% Cream in Adult Subjects With Discoid Lupus Erythematosus, statusModule overallStatus: RECRUITING, startDateStruct date: 2024-04-19, primaryCompletionDateStruct date: 2025-02, completionDateStruct date: 2025-02, studyFirstPostDateStruct date: 2024-02-15, lastUpdatePostDateStruct date: 2024-04-25, sponsorCollaboratorsModule leadSponsor name: Innovaderm Research Inc., class: OTHER, descriptionModule briefSummary: This study is a single-blind, intraindividual study to evaluate the efficacy of ruxolitinib 1.5 % cream in adult subjects with discoid lupus erythematosus., conditionsModule conditions: Discoid Lupus Erythematosus, designModule studyType: INTERVENTIONAL, phases: PHASE2, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, interventionModelDescription: Intra-individual, primaryPurpose: TREATMENT, maskingInfo masking: SINGLE, maskingDescription: This study will be single-blinded. Only the efficacy assessor will be blinded in this study (for subjects with randomized areas). The assessor will only assess efficacy and will not have any other interactions with the subject., whoMasked: OUTCOMES_ASSESSOR, enrollmentInfo count: 20, type: ESTIMATED, armsInterventionsModule interventions name: Ruxolitinib 1.5% cream, interventions name: Application without occlusion in Area 1, interventions name: Application under occlusion at night in Area 2, interventions name: Application under occlusion at night in Area 1, interventions name: Application without occlusion in Area 2, outcomesModule primaryOutcomes measure: Change from baseline in target lesion CLASI-A score, secondaryOutcomes measure: Change from baseline in target lesion CLASI-A score, secondaryOutcomes measure: Proportion of subjects with an erythema score of 0 (absent), secondaryOutcomes measure: Change from baseline in target lesion SADDLE-A, secondaryOutcomes measure: Proportion of subjects with a target lesion CLA-IGA score of 0 (clear) or 1 (almost clear), otherOutcomes measure: Dermatology Life Quality Index (DLQI), otherOutcomes measure: Cutaneous Lupus Erythematosus Quality of Life (CLEQol), otherOutcomes measure: Numeric Rating Scale(NRS), eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Innovaderm Research Inc., status: RECRUITING, city: Montréal, state: Quebec, zip: H2X 2V1, country: Canada, contacts name: Fareheen Chowdhury, MSc, role: CONTACT, phone: 514-521-4285, phoneExt: 341, email: fchowdhury@innovaderm.com, contacts name: Robert Bissonnette, role: PRINCIPAL_INVESTIGATOR, geoPoint lat: 45.50884, lon: -73.58781, hasResults: False